Treatment with the matricellular protein CCN3 blocks and/or reverses fibrosis development in obesity with diabetic nephropathy.

@article{Riser2014TreatmentWT,
  title={Treatment with the matricellular protein CCN3 blocks and/or reverses fibrosis development in obesity with diabetic nephropathy.},
  author={Bruce L. Riser and Feridoon Najmabadi and Kendra Garchow and Jeffrey L. Barnes and Darryl R. Peterson and Ernest J Sukowski},
  journal={The American journal of pathology},
  year={2014},
  volume={184 11},
  pages={2908-21}
}
Fibrosis is at the core of the high morbidity and mortality rates associated with the complications of diabetes and obesity, including diabetic nephropathy (DN), without any US Food and Drug Administration-approved drugs with this specific target. We recently provided the first evidence that the matricellular protein CCN3 (official symbol NOV) functions in a reciprocal manner, acting on the profibrotic family member CCN2 to inhibit fibrosis in a mesangial cell model of DN. Herein, we used the… CONTINUE READING